Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers

Funding: This research was funded by NHS Grampian Endowment Fund grant number NER11101 Acknowledgments: The authors would like to thank the NHS Grampian Breast Cancer Endowment Fund body for supporting the publication of the present manuscript and funding publication fees.Peer reviewedPublisher PD

Impalpable Breast Cancer and Service Delivery during the COVID-19 Pandemic : the Role of Radiofrequency Tag localization

Funding Information: The authors would like to thank Friends of Anchor for their generous grant that enabled the trial of RF tags in Aberdeen, and all the staff in the Unit at Aberdeen Royal Infirmary and BMI Albyn Hospital for making this possible.Peer reviewedPublisher PD

Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer : meta-analysis

Funding The authors have no funding to declare. Acknowledgements The authors acknowledge NHSG Library and Knowledge Services.Peer reviewedPublisher PD

Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer : meta-analysis

The authors acknowledge NHSG Library and Knowledge Services.Peer reviewe

Pseudoangiomatous Stromal Hyperplasia: A Case Report

Pseudoangiomatous stromal hyperplasia (PASH) is a rare benign proliferating breast condition. It was first reported in 1986 when Vuitch, Rosen, and Erlandson described nine cases of benign well-circumscribed, breast masses that simulated vascular lesions consisting of mammary stromal proliferations (Vuitch et al. (1986)). Since then there have been few reported cases of PASH in the literature (Taira et al. (2005)). We describe a large PASH, mimicking inflammatory carcinoma in a young lady that was excised with excellent cosmetic results

The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery

Acknowledgments There is no funding for this project as this is a retrospective review of our practice. This project did not get any grants or funding in the public, commercial or a none profit sector. Open Access via Elsevier agreement.Peer reviewedPublisher PD

Impaired Cardiac and Skeletal Muscle Energetics Following Anthracycline Therapy for Breast Cancer

Acknowledgments The fellow (Dr Gamble) recruited participants, scheduled, coordinated, and performed all clinical imaging investigations, patients skeletal muscle biopsies and venesection, conducted mitochondrial copy number analysis of muscle biopsies under supervision, analyzed all data, performed statistical analyses under supervision, and drafted this article. H. Khan and A. Rudd helped with the investigations and reviewed and contributed to this article. S. Baliga provided the healthy volunteer skeletal muscle biopsies. Dr Ross designed and developed the protocol for cardiac and skeletal muscle spectroscopy. L. Cheyne supervised muscle biopsy analyses. Drs Unger and Linke performed the skeletal muscle transmission electron microscopy and immunofluorescence confocal microscopy investigations. Dr Horgan is the study statistician. Drs Urquhart, Masannat, Elsberger, Fuller, Mustafa, and Sharma identified and recruited participants and reviewed and contributed to this article. Drs Hannah, Sharma, and Saunders contributed to the design of the study. D. Dawson (PI) designed the study, obtained funding (together with Drs Sharma and Masannat) and regulatory approvals, supervised the unfolding of the study, its analyses and revised the article drafts. Sources of Funding Tenovus Scotland G18.01, D. Dawson and Dr Sharma, Friends of Anchor 2019, Grampian National Health Service-Endowments (Drs Sharma and Masannat), British Health Foundation PG/18/35/33786 to D. Dawson funded DG salary and BHF FS/RTF/20/30009 to D. Dawson funded AR salary.Peer reviewedPublisher PD

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

Comprehending the impact of #Breastcancer, #Breastsurgery and related hashtags on Twitter : A content and social network cross-sectional analysis #Breastcancer#Breastsurgery

NHS Grampian Breast Cancer Endowment fund. CRediT authorship contribution statement Stavroula L. Kastora: Study design, Data acquisition, Quality control of data and algorithms, Formal analysis, interpretation, Formal analysis, Manuscript preparation, Manuscript editing, Manuscript review. Andreas Karakatsanis: Conceptualization, Study design, Quality control of data and algorithms, Formal analysis, interpretation, Formal analysis, Manuscript editing, Manuscript review. Yazan A. Masannat: Conceptualization, Study design, Manuscript editing, Manuscript review.Peer reviewedPublisher PD